4-bromo-2-(cyclopropylmethoxy)-1-methoxybenzene | 173406-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-bromo-2-(cyclopropylmethoxy)-1-methoxybenzene
• 英文别名: 4-Bromo-2-cyclopropylmethoxy-1-methoxybenzene
• CAS: 173406-57-0
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: NUAYJFQTVXIVFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(cyclopropylmethoxy)-1-methoxybenzene 在 palladium diacetate 、 potassium carbonate 、 三环己基膦 作用下， 以 N,N-二甲基乙酰胺 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 8.0h， 生成 2-(3-(cyclopropylmethoxy)-4-methoxyphenyl)-7-(2-morpholinoethoxy)benzofuran-6-ol citrate
  参考文献：
  名称：

  Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis

  摘要：

  DOI：

  10.1016/j.bioorg.2024.107474
• 作为产物：
  描述：

  o-(环丙基甲氧基)苯酚 在 溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 4-bromo-2-(cyclopropylmethoxy)-1-methoxybenzene
  参考文献：
  名称：

  Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis

  摘要：

  DOI：

  10.1016/j.bioorg.2024.107474

文献信息

• Pyrrolopyridazinone Compound
  申请人：Hagihara Masahiko

  公开号：US20090036453A1

  公开（公告）日：2009-02-05

  The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.

  本发明公开了一种由式（1）表示的吡咯吡啶二酮化合物：其中，R1代表C1-C2烷基或卤代C1-C2烷基，R2代表C3-C5环烷基、（C3-C5环烷基）C1-C2烷基或C1-C3烷基，R3代表氢原子，或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基，R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团（a）中选择的取代基团取代的C1-C6烷基，可由从取代基团（b）中选择的取代基团取代的C3-C6环烷基，可由从取代基团（b）中选择的取代基团取代的C1-C3烷基，且可由羟基取代，芳香环基或杂芳香环基，每个都可由从取代基团（c）中选择的取代基团取代或由取代基团（c）选择的基团取代的C1-C2烷基，且可由羟基取代，取代基团（a）表示卤素原子、羟基、氰基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、（C3-C6环烷基）C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的氨基基团，取代基团（b）表示羟基或卤素原子，取代基团（c）表示卤素原子、羟基、氰基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的氨基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基，或其药学上可接受的盐。
• Pyrrolopyridazinone compound
  申请人：Hagihara Masahiko

  公开号：US08450319B2

  公开（公告）日：2013-05-28

  The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): useful, for example, as an anti-inflammatory agent or an inhibitor of respiratory tract contraction.

  本发明公开了一种由式(1)表示的吡咯吡啶并噻唑酮化合物：可用作抗炎剂或呼吸道收缩抑制剂。
• [5]-Helistatins: Tubulin-Binding Helicenes with Antimitotic Activity
  作者：James L. Rushworth、Aditya R. Thawani、Elena Fajardo-Ruiz、Joyce C. M. Meiring、Constanze Heise、Andrew J. P. White、Anna Akhmanova、Jochen R. Brandt、Oliver Thorn-Seshold、Matthew J. Fuchter

  DOI：10.1021/jacsau.2c00435

  日期：2022.11.28

  Helicenes are high interest synthetic targets with unique conjugated helical structures that have found important technological applications. Despite this interest, helicenes have had limited impact in chemical biology. Herein, we disclose a first-in-class antimitotic helicene, helistatin 1 (HA-1), where the helicene scaffold acts as a structural mimic of colchicine, a known antimitotic drug. The synthesis

  螺旋烯是备受关注的合成靶标，具有独特的共轭螺旋结构，已找到重要的技术应用。尽管存在这种兴趣，螺旋烯在化学生物学中的影响有限。在此，我们公开了一种一流的抗有丝分裂螺旋烯， helistatin 1 (HA-1) ，其中螺旋烯支架充当已知抗有丝分裂药物秋水仙碱的结构模拟物。该合成通过连续的 Pd 催化偶联反应和 PtCl 2介导的 π-Lewis 酸环异构化进行。在无细胞和活细胞测定中发现HA-1可以阻断微管聚合。这不仅证明了使用螺旋烯作为针对蛋白质靶标的生物活性支架的可行性，而且还表明使用螺旋烯作为联芳基或顺式二苯乙烯的电子等排物（本身是常见的药物和天然产物支架）具有更广泛的潜力。总体而言，这项研究进一步支持了螺旋烯在一系列化学生物应用中的未来机会。
• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。